Letermovir CMV Prophylaxis Associated with Resolution of Valganciclovir-Related Neutropenia in Liver Transplant Recipients (ATC 2026) - Jun 17, 2026 - Abstract #Abstract A220; Pres time: Jun 20, 2026; 05:45 PM - 06:45 PM; Location: Exhibit Hall; "Maintenance immunosuppression was tacrolimus, mycophenolate or azathioprine, and prednisone. CMV prophylaxis consisted of either LTV with acyclovir (LTV) for the entire course, or VGC and LTV sequentially (VGC+LTV)... In this study, LTV CMV prophylaxis was associated with resolution of VGC-related neutropenia in LT recipients without need for G-CSF support and comparable CMV infection risk. These data support LTV as an alternative to VGC for CMV prophylaxis in LT recipients at risk for myelosuppression.Table 1: Characteristics and outcomes of LT patients on LTV only or VGC+LTV for CMV ProphylaxisN (%) or Median (IQR)TotalLTVVGC+LTVN = 24N = 4N = 20CMV RiskHigh17 (71%)3 (75%)14 (70%)Intermediate7 (29%)1 (25%)6 (30%)AntimetaboliteMycophenolate23 (96%)4 (100%)19 (20%)Azathioprine1 (4%)01 (5%)Days on antiviralLTV89 (35, 149)180 (113, 180)66 (22, 120)VGC76 (30, 107)-78 (56, 116)Reason for VGC to LTV changeNeutropenia9 (38%)-9 (47%)Insurance approval10 (42%)-10..."
Clinical • Cytomegalovirus Infection • Hematological Disorders • Infectious Disease • Neutropenia • Solid Organ Transplantation • Transplantation
|
|
W. Shivega; M. Hack; P. Neppala; A. Olyaei; A. Bolognese; C. Enestvedt; E. Maynard; D. Scott; O. Shaked; D. Woodland; C. Connelly
|